Skip to Main Content

Amid ongoing concerns that clinical trial data is too often kept under wraps, an analysis found that most large drug makers continue to do a poor job of sharing study data after new medicines were approved, adding further pressure on the pharmaceutical industry to improve disclosure practices.

Specifically, just three of a dozen companies shared data within a reasonable time frame, according to the analysis published in BMJ. The researchers, who reviewed disclosures for new medicines that were approved in 2015, noted the proportion rose to four after the laggards were given 30 days to make changes. And only four of the companies registered and reported or published the results of all of their trials conducted in patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!